Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types.

Autor: Pilié PG; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Giuliani V; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas., Wang WL; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., McGrail DJ; Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, Ohio., Bristow CA; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas., Ngoi NYL; Department of Investigational Cancer Therapeutics (Phase I Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kyewalabye K; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wani KM; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Le H; Department of Investigational Cancer Therapeutics (Phase I Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Campbell E; Department of Investigational Cancer Therapeutics (Phase I Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Sanchez NS; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Yang D; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Gheeya JS; The University of Texas Health Science Center at Houston, Houston, Texas., Goswamy RV; The University of Texas Health Science Center at Houston, Houston, Texas., Holla V; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Shaw KR; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Meric-Bernstam F; Department of Investigational Cancer Therapeutics (Phase I Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Liu CY; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas., Ma X; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas., Feng N; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas., Machado AA; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas., Bardenhagen JP; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas., Vellano CP; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas., Marszalek JR; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas., Rajendra E; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Piscitello D; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Johnson TI; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Likhatcheva M; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Elinati E; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Majithiya J; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Neves J; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Grinkevich V; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Ranzani M; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Luzarraga MR; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Boursier M; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Armstrong L; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Geo L; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Lillo G; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Tse WY; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Lazar AJ; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kopetz SE; Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Geck Do MK; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas., Lively S; ChemPartner Corporation, San Francisco, California., Johnson MG; ChemPartner Corporation, San Francisco, California., Robinson HMR; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Smith GCM; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Carroll CL; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas., Di Francesco ME; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas., Jones P; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas., Heffernan TP; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas., Yap TA; Department of Investigational Cancer Therapeutics (Phase I Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 May 15; Vol. 30 (10), pp. 2121-2139.

Assessment of Four Obturation Methods in Deciduous Teeth Using Digital Radiography: An In Vivo Study

Autor: Thabitha Rani, Srujana P Mudusu, Kiranmayi Merum, Rajendra E Reddy, Srikanth S Raju, Ajay M Tulluru

Publikováno v: International Journal of Clinical Pediatric Dentistry. 15:S52-S56

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cdede5dba5adbc7c6e93bb5b461fb520
https://doi.org/10.5005/jp-journals-10005-2132

Effect of Digitalized Previsit Imagery on Behavior of Children in the Dental Operatory

Autor: Rajendra E, Reddy, Kiranmayi, Merum, Srujana Palicarp, Mudusu, S, Srikanth, Poornima, Dubey

Publikováno v: International journal of clinical pediatric dentistry. 14(Suppl 2)

The present study was aimed to determine the impact of exposure to digitalized previsit imagery technique on the anticipatory dental anxiety levels of children.40 children, aged 4-8 years requiring noninvasive dental treatment were included in the st

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23b679ab51f04d1a4d22610b7a8fdf04
https://pubmed.ncbi.nlm.nih.gov/35645482

Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models.

Autor: Rodriguez-Berriguete G; Department of Oncology, University of Oxford, Oxford, United Kingdom., Ranzani M; Artios Pharma, Babraham Research Campus, Cambridge, United Kingdom., Prevo R; Department of Oncology, University of Oxford, Oxford, United Kingdom., Puliyadi R; Department of Oncology, University of Oxford, Oxford, United Kingdom., Machado N; Department of Oncology, University of Oxford, Oxford, United Kingdom., Bolland HR; Department of Oncology, University of Oxford, Oxford, United Kingdom., Millar V; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom., Ebner D; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom., Boursier M; Artios Pharma, Babraham Research Campus, Cambridge, United Kingdom., Cerutti A; Artios Pharma, Babraham Research Campus, Cambridge, United Kingdom., Cicconi A; Artios Pharma, Babraham Research Campus, Cambridge, United Kingdom., Galbiati A; Artios Pharma, Babraham Research Campus, Cambridge, United Kingdom., Grande D; Artios Pharma, Babraham Research Campus, Cambridge, United Kingdom., Grinkevich V; Artios Pharma, Babraham Research Campus, Cambridge, United Kingdom., Majithiya JB; Artios Pharma, Babraham Research Campus, Cambridge, United Kingdom., Piscitello D; Artios Pharma, Babraham Research Campus, Cambridge, United Kingdom., Rajendra E; Artios Pharma, Babraham Research Campus, Cambridge, United Kingdom., Stockley ML; Artios Pharma, Babraham Research Campus, Cambridge, United Kingdom., Boulton SJ; Artios Pharma, Babraham Research Campus, Cambridge, United Kingdom.; The Francis Crick Institute, London, United Kingdom., Hammond EM; Department of Oncology, University of Oxford, Oxford, United Kingdom., Heald RA; Artios Pharma, Babraham Research Campus, Cambridge, United Kingdom., Smith GCM; Artios Pharma, Babraham Research Campus, Cambridge, United Kingdom., Robinson HMR; Artios Pharma, Babraham Research Campus, Cambridge, United Kingdom., Higgins GS; Department of Oncology, University of Oxford, Oxford, United Kingdom.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Apr 14; Vol. 29 (8), pp. 1631-1642.

Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase Theta.

Autor: Stockley ML; Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K., Ferdinand A; Cancer Research Horizons Therapeutic Innovation, Jonas Webb Building, Babraham Research Campus, CambridgeCB22 3AT, U. K., Benedetti G; Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K., Blencowe P; Cancer Research Horizons Therapeutic Innovation, Jonas Webb Building, Babraham Research Campus, CambridgeCB22 3AT, U. K., Boyd SM; CompChem Solutions Ltd, St John's Innovation Centre, Cowley Rd, CambridgeCB4 0WS, U. K., Calder M; Cancer Research Horizons Therapeutic Innovation, Jonas Webb Building, Babraham Research Campus, CambridgeCB22 3AT, U. K., Charles MD; Cancer Research Horizons Therapeutic Innovation, Jonas Webb Building, Babraham Research Campus, CambridgeCB22 3AT, U. K., Edwardes LV; Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K., Ekwuru T; Cancer Research Horizons Therapeutic Innovation, Jonas Webb Building, Babraham Research Campus, CambridgeCB22 3AT, U. K., Finch H; Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K., Galbiati A; Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K., Geo L; Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K., Grande D; Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K., Grinkevich V; Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K., Holliday ND; Excellerate Bioscience Ltd., BioCity, Pennyfoot Street, NottinghamNG1 1GF, U. K., Krajewski WW; Cancer Research Horizons Therapeutic Innovation, The Francis Crick Institute, 1 Midland Road, LondonNW1 1AT, U. K., MacDonald E; Cancer Research Horizons Therapeutic Innovation, Jonas Webb Building, Babraham Research Campus, CambridgeCB22 3AT, U. K., Majithiya JB; Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K., McCarron H; Cancer Research Horizons Therapeutic Innovation, Jonas Webb Building, Babraham Research Campus, CambridgeCB22 3AT, U. K., McWhirter CL; Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K., Patel V; Excellerate Bioscience Ltd., BioCity, Pennyfoot Street, NottinghamNG1 1GF, U. K., Pedder C; Cancer Research Horizons Therapeutic Innovation, Jonas Webb Building, Babraham Research Campus, CambridgeCB22 3AT, U. K., Rajendra E; Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K., Ranzani M; Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K., Rigoreau LJM; Cancer Research Horizons Therapeutic Innovation, Jonas Webb Building, Babraham Research Campus, CambridgeCB22 3AT, U. K., Robinson HMR; Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K., Schaedler T; Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K., Sirina J; Excellerate Bioscience Ltd., BioCity, Pennyfoot Street, NottinghamNG1 1GF, U. K., Smith GCM; Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K., Swarbrick ME; Cancer Research Horizons Therapeutic Innovation, Jonas Webb Building, Babraham Research Campus, CambridgeCB22 3AT, U. K., Turnbull AP; Cancer Research Horizons Therapeutic Innovation, The Francis Crick Institute, 1 Midland Road, LondonNW1 1AT, U. K., Willis S; Cancer Research Horizons Therapeutic Innovation, The Francis Crick Institute, 1 Midland Road, LondonNW1 1AT, U. K., Heald RA; Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K.

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2022 Oct 27; Vol. 65 (20), pp. 13879-13891. Date of Electronic Publication: 2022 Oct 06.